Abstract
Haemophilus influenzae strains with varied ampicillin resistance and beta-lactamase production patterns were tested against three investigational fluorinated quinolones (CI-960, fleroxacin, temafloxacin) using Haemophilus Test Medium (HTM) and National Committee for Clinical Laboratory Standards (NCCLS) methods. The disk diffusion zones and MICs were compared and regression statistics and scattergrams generated. The rank order of the agents according to activity againstHaemophilus influenzae was CI-960 (MIC50 0.002 µg/ml) > temafloxacin (MIC50 0.015 µg/ml) > fleroxacin (MIC50 0.03 µg/ml). The recommended susceptibility interpretive criteria for the 5-µg disks of each drug were: for CI-960 ≥ 23 mm (MIC correlate ≤ 1 µg/ml); for fleroxacin ≥ 19 mm (MIC correlate ≤ 2 µg/ml); and for temafloxacin ≥ 16 mm (MIC correlate ≤ 2 µg/ml). All recentHaemophilus influenzae isolates tested were susceptible to these potent fluoroquinolones and no interpretive errors were observed.
Similar content being viewed by others
References
Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS: Antimicrobial resistance among respiratory isolates ofHaemophilus influenzae, Moraxella catarrhalis andStreptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 1990, 34: 2075–2080.
Cohen AM, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL: In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816 and PD 127391. Diagnostic Microbiology and Infectious Disease 1991, 14: 245–258.
Fuchs PC, Jones RN, Barry AL, Ayers LW, Gavan TL, Gerlach EH, Thornsberry C: Ro 23-6240 (AM833) a new fluoroquinolone: in vitro antibacterial activity and tentative disk diffusion interpretive criteria. Diagnostic Microbiology and Infectious Disease 1987, 7: 29–35.
Hardy DJ, Swanson RN, Hensey DM, Ramer NR, Bower RR, Hanson CW, Chu DTW, Fernandes PB: Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrobial Agents and Chemotherapy 1987, 31: 1768–1774.
Hirai K, Aoyama H, Hosaka M, Oomori Y, Niwata Y, Suzue S, Irikura T: In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrobial Agents and Chemotherapy 1986, 29: 1059–1066.
National Committee for Clinical Laboratory Standards: Development of in vitro susceptibility testing criteria and quality control parameters. Tentative guideline M23-T. NCCLS, Villanova, PA, 1989.
National Committee for Clinical Laboratory Standards: Performance standards for antimicrobic disk susceptibility tests, 4th ed. Approved standard M2-A4. NCCLS, Villanova, PA, 1990.
National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A2. NCCLS, Villanova, PA, 1990.
Jorgensen JH, Redding JS, Maher LA, Howell AW: Improved medium for antimicrobial susceptibility testing ofHaemophilus influenzae. Journal of Clinical Microbiology 1987, 25: 2105–2113.
National Committee for Clinical Laboratory Standards: Informational supplement M100-53. NCCLS, Villanova, PA, 1991.
Jones RN, Erwin ME, Barrett MS: Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-µg disks. Diagnostic Microbiology and Infectious Disease 1992, 15: 379–382.
Jones RN, Washington JA, Pfaller MA, Koontz FP, Gerlach EH, Erwin ME: Quality control guidelines for Haemophilus Test Medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246. Journal of Antimicrobial Chemotherapy 1991, 27: 390–392.
Bale MJ, Jones RN, Erwin ME, Koontz FP, Gerlach EH, Murray PA, Washington JA: Disk diffusion quality control guidelines forHaemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin. Journal of Clinical Microbiology 1992, 30: 744–745.
Bale MJ, Jones RN, Erwin ME, Koontz FP, Gerlach EH, Murray PR, Washington JA: MIC quality control guidelines forHaemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500 and trospectomycin. Journal of Clinical Microbiology 1992, 30: 225–226.
Barry AL, Jones RN: Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests. Journal of Clinical Microbiology 1989, 27: 2861–2863.
Mendelman PM, Wiley EA, Stull TL, Clausen C, Chiffan DO, Onay O: Problems with current recommendations for susceptibility testing ofHaemophilus influenzae. Antimicrobial Agents and Chemotherapy 1990, 34: 1480–1484.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barrett, M.S., Jones, R.N. Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests withHaemophilus influenzae . Eur. J. Clin. Microbiol. Infect. Dis. 11, 462–465 (1992). https://doi.org/10.1007/BF01961865
Issue Date:
DOI: https://doi.org/10.1007/BF01961865